Astellas, LabCentral launch Future Innovator Prize

By The Science Advisory Board staff writers

August 18, 2021 -- Astellas Venture Management, a wholly owned subsidiary of Astellas Pharma, and LabCentral are collaborating to launch the Future Innovator Prize, formerly known as the Astellas Golden Ticket Competition.

The Future Innovator Prize offers entrepreneurial scientists and emerging biotechnology startups one-year usage of LabCentral's laboratory facilities in Cambridge, MA, as well as access to Astellas' R&D capabilities and business leaders. The prize will be awarded to two pioneering scientists with innovative research that complements Astellas' areas of interests, including oncology, immunology, and neuroscience.

Astellas Venture Management became a gold-level sponsor of LabCentral in 2019. LabCentral is a private nonprofit founded in 2013 as a launchpad for high-potential life sciences and biotech startups. The organization operates a 100,000-sq-ft facility in Cambridge, MA, where it houses lab and office space for up to 70 startups comprising approximately 500 scientists and entrepreneurs.

Applications can be submitted beginning August 18, 2021, and ending on September 20, 2021.

Amgen to sponsor Golden Ticket award at BioLabs LA
Amgen is sponsoring a three-year Golden Ticket award at BioLabs LA at the Lundquist Institute in West Carson, CA, to support the development of new therapies,...
Astellas announces 'golden ticket' winners
Astellas Venture Management, a subsidiary of Astellas Pharma and LabCentral, announced that Axonis Therapeutics and Tenza are the 2020 winners of the...
Astellas, MBC BioLabs call for scientists to enter 'Golden Ticket Competition'
Astellas Venture Management and Mission Bay Capital BioLabs (MBC BioLabs) are collaborating again on the "Golden Ticket Competition," which offers up...

Copyright © 2021 scienceboard.net


Conferences
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter